September 16, 2018 - By Nadine Davis

The stock of ARNO THERAPEUTICS INC (OTCMKTS:ARNI) registered an increase of 600% in short interest. ARNI’s total short interest was 700 shares in September as published by FINRA. Its up 600% from 100 shares, reported previously.

It closed at $0.003 lastly. It is down 0.00% since September 16, 2017 and is . It has underperformed by 15.62% the S&P500.

Arno Therapeutics, Inc., a biopharmaceutical company, develops products for the treatment of cancer and other life threatening diseases. The company has market cap of $148,049. The company's product development pipeline includes Onapristone, a type 1 anti-progestin hormone blocker that is in Phase I/II clinical study for the treatment of breast, endometrial, and others solid tumors in post-menopausal women; and advanced castration-resistant prostate cancer in men. It currently has negative earnings. The Company’s product development pipeline also consists of AR-12, an orally available cancer treatment, which has completed Phase I clinical study for the treatment of solid tumors and hematological malignancies, as well as in Pre-clinical studies for the treatment of various anti-microbial targets.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.